Overview
- Novartis began construction on a 46,000‑square‑foot radioligand therapy facility in Denton, Texas, marking a new U.S. production hub.
- The plant is slated to start operations in 2028 and will supply patients across the southern United States.
- The company is building a distributed network because the radioactive components in these drugs decay quickly, which leaves a narrow shipping window.
- Novartis already supplies two FDA‑approved radioligand therapies, Lutathera for neuroendocrine tumors and Pluvicto for a form of prostate cancer, with local clinicians reporting strong patient outcomes.
- Officials from the U.S. and Switzerland joined state and city leaders at the groundbreaking, underscoring support for a multi‑site expansion that includes facilities in California, Indiana, New Jersey, and a planned site in Florida.